These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 34660129)
1. An Interesting Case of Immunoglobulin G4-Related Retroperitoneal Fibrosis Treated With Rituximab. Hamdan A; Moeen Z; Tariq H; Olson O; Matute-Martinez C; Sidhu M; Mukkera S Cureus; 2021 Sep; 13(9):e17940. PubMed ID: 34660129 [TBL] [Abstract][Full Text] [Related]
2. Rituximab for idiopathic and IgG4-related retroperitoneal fibrosis. Wallwork R; Wallace Z; Perugino C; Sharma A; Stone JH Medicine (Baltimore); 2018 Oct; 97(42):e12631. PubMed ID: 30334947 [TBL] [Abstract][Full Text] [Related]
3. Rituximab for the treatment of IgG4-related disease: lessons from 10 consecutive patients. Khosroshahi A; Carruthers MN; Deshpande V; Unizony S; Bloch DB; Stone JH Medicine (Baltimore); 2012 Jan; 91(1):57-66. PubMed ID: 22210556 [TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G4-related retroperitoneal fibrosis. Angarola E; Valeo Chulvi M; Peuchot V; García Rivello H; Jauk F Medicina (B Aires); 2022; 82(1):91-98. PubMed ID: 35037866 [TBL] [Abstract][Full Text] [Related]
5. Atypical Presentation of Retroperitoneal Fibrosis Causing Colonic Obstruction: A Case Report. Achrak E; Manville E; Ayyat M; Toribio RD Cureus; 2024 Mar; 16(3):e55621. PubMed ID: 38586788 [TBL] [Abstract][Full Text] [Related]
6. IgG4-related retroperitoneal fibrosis: A case report of a challenging disease. Farook S; Jilani MSA; Islam MK; Rahman S; Ashraf R; Mendiratta N; Rawal SK Clin Case Rep; 2023 Sep; 11(9):e7865. PubMed ID: 37663821 [TBL] [Abstract][Full Text] [Related]
7. Rituximab for retroperitoneal fibrosis due to IgG4-related disease: A case report and literature review. Almeqdadi M; Al-Dulaimi M; Perepletchikov A; Tomera K; Jaber BL Clin Nephrol Case Stud; 2018; 6():4-10. PubMed ID: 29845002 [TBL] [Abstract][Full Text] [Related]
8. A case of IgG4-related retroperitoneal fibrosis with significant involvement of the abdominal aorta-a clinical and diagnostic challenge. Gormley S; Bravo PT; Kos X; Solanki K; Khashram M J Vasc Surg Cases Innov Tech; 2022 Jun; 8(2):275-280. PubMed ID: 35586678 [TBL] [Abstract][Full Text] [Related]
9. Clinical Perspectives on IgG4-Related Disease and Its Classification. Katz G; Stone JH Annu Rev Med; 2022 Jan; 73():545-562. PubMed ID: 34669430 [TBL] [Abstract][Full Text] [Related]
11. No specific imaging pattern can help differentiate IgG4-related disease from idiopathic retroperitoneal fibrosis: 18 histologically proven cases. Forestier A; Buob D; Mirault T; Puech P; Gnemmi V; Launay D; Hachulla E; Hatron PY; Lambert M Clin Exp Rheumatol; 2018; 36(3):371-375. PubMed ID: 29465374 [TBL] [Abstract][Full Text] [Related]
12. [Successful therapy of retroperitoneal fibrosis due to IgG4-related disease with rituximab, cyclophosphamide and glucocorticoids followed by maintenance therapy wit ritutixmab]. Adam Z; Čermák A; Petrášová H; Řehák Z; Koukalová R; Fojtík Z; Pour L; Boichuk I; Krejčí M; Král Z; Benda P Vnitr Lek; 2023; 69(E-3):4-15. PubMed ID: 37468330 [TBL] [Abstract][Full Text] [Related]
13. IgG4-related retroperitoneal fibrosis: a newly characterized disease. Lian L; Wang C; Tian JL Int J Rheum Dis; 2016 Nov; 19(11):1049-1055. PubMed ID: 27125330 [TBL] [Abstract][Full Text] [Related]
15. IgG4-Related Kidney Disease: A Diagnostic Conundrum Successfully Treated With Steroids and Rituximab. Chellappan A; Bhawane A; Sharma A; Rokade R Cureus; 2024 Jan; 16(1):e52000. PubMed ID: 38344630 [TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab biosimilar (CT-P10) in IgG4-related disease: an observational prospective open-label cohort study. Della-Torre E; Lanzillotta M; Campochiaro C; Di-Colo G; Mancuso G; Capurso G; Falconi M; Dagna L Eur J Intern Med; 2021 Feb; 84():63-67. PubMed ID: 33386207 [TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of maintenance therapy with Rituximab for IgG4-related disease. Campochiaro C; Della-Torre E; Lanzillotta M; Bozzolo E; Baldissera E; Milani R; Arcidiacono PG; Crippa S; Falconi M; Dagna L Eur J Intern Med; 2020 Apr; 74():92-98. PubMed ID: 31901297 [TBL] [Abstract][Full Text] [Related]
18. Clinical features of IgG4-related retroperitoneal fibrosis among 407 patients with IgG4-related disease: a retrospective study. Liu Y; Zhu L; Wang Z; Zeng Q; Yang F; Gao J; Wang Z; Wang K; Ren L; Zhang Y; Zhang S; Wang Y; Shen D; Xia C; Yu G; Li Z Rheumatology (Oxford); 2021 Feb; 60(2):767-772. PubMed ID: 32793960 [TBL] [Abstract][Full Text] [Related]
19. Effectiveness of tofacitinib monotherapy for patients with IgG4-RD or idiopathic retroperitoneal fibrosis. Cao X; Li S; Wan J; Yu Z; Dong G; Zhou W Clin Exp Rheumatol; 2024 Sep; 42(9):1736-1743. PubMed ID: 38530663 [TBL] [Abstract][Full Text] [Related]
20. Therapeutic Uses of Rituximab and Clinical Features in Immunoglobulin G4-Related Disease: A Systematic Review. Patel U; Saxena A; Patel D; Ayesha IE; Monson NR; Klair N; Yu AK Cureus; 2023 Sep; 15(9):e45044. PubMed ID: 37701160 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]